Hyderabad News Desk

DelveInsight Business Research LLP

DelveInsight’s “Vernal Keratoconjunctivitis- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Vernal Keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal Keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Vernal Keratoconjunctivitis Epidemiology 

• The prevalence of vernal keratoconjunctivitis varies from region to region. It is more commonly seen in tropical and sub-tropical countries and is more prevalent in warm and dry areas. The prevalence reported from cooler countries like the United States is 0.29/10000 population. A prevalence varying from 1.2 to 12.6 cases per 10000 has been reported in Europe. The disease is much more common in countries like Africa, with a reported prevalence varying from 2 to 37%

• The prevalence of corneal complications, thus predisposing to blindness-related sequelae, also varies from region to region. The prevalence rates reported from Europe range from 0.30-2.26. While those reported from Italy vary from 0.4 to 4.8, and from Norway to as low as 0.1 to 1.0

Key Highlights Vernal Keratoconjunctivitis Market 

• Key Companies working in the  Vernal Keratoconjunctivitis market are Allakos, Astellas Pharma, and many others.

• Key Therapies in  Vernal Keratoconjunctivitis are NOVA22007, Lactobacillus Rhamnosus GG, Tacrolimus, and many others.

 Vernal Keratoconjunctivitis Overview

Vernal keratoconjunctivitis is a common bilateral atopic disease clinically characterized by limbal papillae (Horner Tranta dots) having papillary, limbal, and mixed forms.The most consistent presentation is itching, and the episodes are often recurrent, usually perennial in the beginning, and become chronic over time. The males are more often affected than females. Histopathology shows eosinophils in the conjunctival secretions. The treatment comprises topical antihistamines and mast cell inhibitors.

Click here to learn more about the  Vernal Keratoconjunctivitis Market Landscape

The Report Covers the  Vernal Keratoconjunctivitis  Epidemiology Segmented by:

•  Vernal Keratoconjunctivitis prevalent cases  

•  Vernal Keratoconjunctivitis incident cases 

•  Vernal Keratoconjunctivitis  treatment cases 

•  Vernal Keratoconjunctivitis diagnosed cases 

Vernal Keratoconjunctivitis Market Outlook 

The Vernal Keratoconjunctivitis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Vernal Keratoconjunctivitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Vernal Keratoconjunctivitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Vernal Keratoconjunctivitis market in 7MM is expected to change in the study period 2019-2032.

Key Companies Working in the Vernal Keratoconjunctivitis Market

• Allakos Inc 

• Astellas Pharma

And many others.

 Vernal Keratoconjunctivitis Therapies Covered and Analyzed in the Report

• NOVA22007

• Lactobacillus Rhamnosus GG

• Tacrolimus

And many others.

Learn more about the Key Companies and Emerging Therapies in the  Vernal Keratoconjunctivitis Market

Table of Contents 

1. Key Insights 

2.  Vernal Keratoconjunctivitis Introduction 

3.  Executive Summary of Vernal Keratoconjunctivitis             

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Vernal Keratoconjunctivitis Emerging Therapies

7.  Vernal Keratoconjunctivitis Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @  Vernal Keratoconjunctivitis Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services